AMED Stock Recent News
AMED LATEST HEADLINES
NEW YORK , Aug. 14, 2025 /PRNewswire/ -- Twilio Inc. (NYSE: TWLO) will replace Amedisys Inc. (NASD: AMED) in the S&P MidCap 400 effective prior to the opening of trading on Tuesday, August 19. S&P 500 and S&P 100 constituent UnitedHealth Group Inc. (NYSE: UNH) acquired Amedisys in a deal completed today.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Although the revenue and EPS for Amedisys (AMED) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Amedisys (AMED) came out with quarterly earnings of $1.54 per share, beating the Zacks Consensus Estimate of $1.39 per share. This compares to earnings of $1.32 per share a year ago.
BATON ROUGE, La., July 29, 2025 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and six-month periods ended June 30, 2025.
Amedisys' high Quality of Patient Care and Patient Satisfaction star ratings bring optimism to investors. Yet, a dull macroeconomic condition adds to the worry.
Investors interested in Medical - Outpatient and Home Healthcare stocks are likely familiar with Amedisys (AMED) and Chemed (CHE). But which of these two stocks offers value investors a better bang for their buck right now?
Here is how Amedisys (AMED) and BrightSpring Health Services, Inc. (BTSG) have performed compared to their sector so far this year.
Amedisys delivers first-quarter top-line growth across three of its segments, namely Home Health, Hospice and High Acuity Care.